Search research articles
Contact Us
Filters
Showing results (21-30 of 211) with videos related to
Page
of 22
Sort By:
Cleveland Clinic Journal of Medicine
|
April 22, 2015
Denosumab: a novel antiresorptive drug for osteoporosis
Ernest Suresh, Bo Abrahamsen
Calcified Tissue International
|
September 30, 2019
The Latest Evidence from Vitamin D Intervention Trials for Skeletal and Non-skeletal Outcomes
Arvind Sami, Bo Abrahamsen
Annals of the New York Academy of Sciences
|
August 16, 2016
Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least?
Michael Pazianas, Bo Abrahamsen
JBMR Plus
|
June 20, 2022
Erratum: Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
Alexander J Rodríguez, Bo Abrahamsen
JBMR Plus
|
July 14, 2021
Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
Alexander J Rodríguez, Bo Abrahamsen
Ugeskrift for Laeger
|
March 10, 2004
[Osteodensitometry]
Bo Abrahamsen, Kim Torsten Brixen
Current Opinion in Pharmacology
|
February 26, 2013
The bisphosphonates: risks and benefits of long term use
Anne Pernille Hermann, Bo Abrahamsen
Maturitas
|
November 8, 2018
Vitamin D supplementation for musculoskeletal health outcomes in adults - The end of the beginning?
Bo Abrahamsen, Nicholas C Harvey
Current Rheumatology Reports
|
February 24, 2012
Disentangling the emerging evidence around atypical fractures
Bo Abrahamsen, Emma M Clark
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
February 4, 2016
Patients With Atypical Femur Fractures Have the Same Mortality as the Background Population--Drug-Channeling Bias, Bisphosphonate Effects, and Public Health Implications
Bo Abrahamsen, Daniel Prieto-Alhambra
Page
of 22
Search research articles
Search
Showing results (21-30 of 211) with videos related to
Sort By:
Page
of 22
Cleveland Clinic Journal of Medicine
|
April 22, 2015
Denosumab: a novel antiresorptive drug for osteoporosis
Ernest Suresh, Bo Abrahamsen
Calcified Tissue International
|
September 30, 2019
The Latest Evidence from Vitamin D Intervention Trials for Skeletal and Non-skeletal Outcomes
Arvind Sami, Bo Abrahamsen
Annals of the New York Academy of Sciences
|
August 16, 2016
Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least?
Michael Pazianas, Bo Abrahamsen
JBMR Plus
|
June 20, 2022
Erratum: Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
Alexander J Rodríguez, Bo Abrahamsen
JBMR Plus
|
July 14, 2021
Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
Alexander J Rodríguez, Bo Abrahamsen
Ugeskrift for Laeger
|
March 10, 2004
[Osteodensitometry]
Bo Abrahamsen, Kim Torsten Brixen
Current Opinion in Pharmacology
|
February 26, 2013
The bisphosphonates: risks and benefits of long term use
Anne Pernille Hermann, Bo Abrahamsen
Maturitas
|
November 8, 2018
Vitamin D supplementation for musculoskeletal health outcomes in adults - The end of the beginning?
Bo Abrahamsen, Nicholas C Harvey
Current Rheumatology Reports
|
February 24, 2012
Disentangling the emerging evidence around atypical fractures
Bo Abrahamsen, Emma M Clark
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
February 4, 2016
Patients With Atypical Femur Fractures Have the Same Mortality as the Background Population--Drug-Channeling Bias, Bisphosphonate Effects, and Public Health Implications
Bo Abrahamsen, Daniel Prieto-Alhambra
Page
of 22